LIBRA-seq for High-Throughput bNAb Identification in Guinea Pigs
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for studying vaccine efficacy in guinea pigs are inadequate, particularly in determining broadly neutralizing antibodies, as they rely on polyclonal neutralizing responses and lack high-throughput, reproducible tools for monoclonal antibody analysis, which hinders the development of effective HIV-1 vaccines.
Innovation Solution
A method involving immunization with a cocktail of viral strain antigens, isolation of antigen-positive IgG-expressing B-cells, labeling with unique antigen barcodes, and subsequent single-cell sequencing to identify broadly neutralizing antibodies using the LIBRA-seq platform, which aligns antibody sequences with reference libraries and determines binding affinity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If polyclonal neutralizing response measurement is used to evaluate vaccine efficacy, then the assessment is simple and rapid, but it misses the nuanced contributions of rare desirable antibodies and lacks monoclonal-level resolution
Solution Approach 1:
The patent segments the polyclonal antibody response into individual monoclonal antibodies through single-cell sorting and isolation. Each B cell is separated and its antibody sequence is individually determined, allowing rare desirable antibodies to be identified and characterized without being masked by the bulk polyclonal response.
Solution Approach 2:
The patent introduces next-generation sequencing technology as an intermediary between polyclonal response measurement and monoclonal antibody characterization. This enables high-throughput analysis of numerous individual antibody sequences from sorted B cells, bridging the gap between simple bulk measurement and detailed monoclonal analysis.
2Measurement precision
If single-cell sorting into 96-well plates is used for antibody sequencing, then monoclonal-level analysis is achieved, but the throughput is limited and information to down-select candidates is insufficient
Solution Approach 1:
The patent transitions from traditional 96-well plate formatting to a high-throughput sequencing dimension by pooling sorted B cells and their associated antigen information for mass parallel sequencing. This dimensional shift enables simultaneous analysis of hundreds or thousands of monoclonal antibodies rather than processing them sequentially in low-throughput formats.
Solution Approach 2:
The patent combines multiple pieces of information (antibody sequence, antigen specificity, B cell identity) into integrated data structures that can be processed in parallel. By merging the sorting, sequencing, and analysis steps into a coordinated high-throughput workflow, the system achieves both monoclonal resolution and high productivity.
3Reliability
If rare bNAb-producing B cell lineages are targeted for activation, then the desired broadly neutralizing antibodies can be elicited, but the probability of finding and activating these rare lineages is extremely low
Solution Approach 1:
The patent performs preliminary enrichment of antigen-specific B cells through flow sorting before sequencing. By pre-selecting B cells that bind to the immunizing antigens and removing non-specific cells, the system increases the proportion of relevant B cell lineages in the sample, making rare bNAb producers more likely to be captured and identified.
Solution Approach 2:
The patent implements a feedback loop where sequencing results inform subsequent vaccine design and immunogen selection. Identified bNAb sequences and their antigen specificities feed back into optimizing future vaccine formulations to better elicit these rare but desirable antibody lineages, progressively improving the reliability of bNAb elicitation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables the identification and characterization of broadly neutralizing antibodies at a high-throughput level, facilitating the development of vaccine compositions that elicit immune responses in guinea pigs and potentially improving HIV-1 vaccine efficacy.
Implementation Method 1
isolating antigen-positive IgG-expressing B-cells from the guinea pigs immunized to the viral strain antigens using IgG positive/IgM negative flow panel
Implementation Method 2
isolating antigen-positive IgG-expressing B-cells from the guinea pigs immunized to the viral strain antigens using IgG positive/IgM negative flow panel
Data Source
AI summary
Disclosed herein are methods of determining broadly neutralizing antibodies, antigen specific cell sorting and developing vaccine compositions in a guinea pig model system using LIBRA-seq.